ALTIMMUNE INC

Altimmune Inc: navigating biotech volatility while pioneering peptide therapeutics for obesity, NASH and chronic hepatitis B, with stock under pressure but high potential upside.

Altimmune’s dual Phase‑2 wins in pemvidutide and a GLP‑1 peptide cut alcohol use by up to 45%, spotlighting its promise for obesity, NASH, and liver disease.

Altimmune’s peptide‑based therapies target obesity, NASH and liver disease, positioning the biotech firm as a rising star for investors and patients alike.

Altimmune partners with a blockchain logistics platform to secure real‑time tracking and scale peptide‑based immunotherapies for liver disease, obesity, and more.

Altimmune, Inc. develops peptide‑based therapeutics for obesity, NASH, chronic hepatitis B and liver diseases, navigating biotech volatility while advancing clinical trials worldwide.

Altimmune’s peptide‑based pipeline targets NAFLD, hepatitis B and other liver disorders, poised to fill diagnostic gaps and meet unmet needs in liver disease therapy.

Altimmune’s Q3 2025 earnings beat expectations, a flexible Phase‑III design for pemvidutide is set, and a new leadership team drives its focus on obesity and liver disease, positioning the biopharma for growth and investor interest.

Altimmune Inc., a clinical-stage biopharmaceutical company, is trading at a low price due to a lack of recent developments, regulatory filings, or partnership announcements, making it a high-risk bet for investors.

Altimmune Inc. is facing a series of corporate challenges, including a failed clinical trial, a shareholder-led legal investigation, and market volatility, but is responding with a share-repurchase program and ongoing clinical development.

Altimmune Inc. is set to release its Q1 2025 financial results on May 13, 2025, a critical moment for the biopharmaceutical company as it seeks to reassure investors and stakeholders amidst a volatile market and intense competition.